Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06155643 · ClinicalTrials.gov registry record · NA

EKO SENSORA: Detecting Clinically Significant Murmurs

A NA study of Heart Murmurs, sponsored by Corewell Health South.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
1
Study location

NCT06155643: Recruiting NA study of Heart Murmurs, sponsored by Corewell Health South.

NCT06155643 is a NA study of Heart Murmurs that is actively recruiting participants, run by Corewell Health South. The registered enrollment target is 300 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06155643, a NA study of Heart Murmurs, is actively recruiting participants, sponsored by Corewell Health South.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

The Eko Artificial Intelligence (AI) has primarily been evaluated in the primary care setting. The digital stethoscope records a phonocardiogram of heart sounds of the patient and uses machine learning artificial intelligence to identify if there are abnormalities present (Eko Health, 2023). The Eko SENSORA will be tested in the emergency department. Chest pain, fatigue, shortness of breath and syncope are all symptoms that could indicate a cardiac dysfunction. The hypothesis is that this device will allow us increased ability to detect valvular heart disease that is clinically significant.

Conditions Studied

Interventions

  • DEVICE Eko Sensora

Study Locations (1)

Michigan

  • Corewell Health Lakeland - Saint Joseph

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2023-10-26
Est. Completion 2026-07-26
Phase NA
Corewell Health South

12 total trials

What NCT06155643 shows while recruiting

NCT06155643 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Heart Murmurs appearing as the primary indexed condition, and to 1 intervention - of which Eko Sensora is the first listed.

NCT06155643 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT06155643 about?

NCT06155643 is a clinical study titled "EKO SENSORA: Detecting Clinically Significant Murmurs". The Eko Artificial Intelligence (AI) has primarily been evaluated in the primary care setting. The digital stethoscope records a phonocardiogram of heart sounds of the patient and uses machine learning artificial intelligence to identify if there are abnormalities present (Eko Health, 2023). The Ek...

What is the current status of trial NCT06155643?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2023-10-26. Estimated completion is 2026-07-26.

What conditions does trial NCT06155643 study?

This clinical trial studies the following conditions: Heart Murmurs.

What interventions are being tested in trial NCT06155643?

The interventions under investigation include: Eko Sensora (DEVICE).

Who is sponsoring clinical trial NCT06155643?

This trial is sponsored by Corewell Health South, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06155643 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Murmurs

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06155643's enrollment target sits among peer trials

300 330th of 2000 higher than 1,631 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06155643, the US trial registry maintained by the National Library of Medicine. NCT06155643 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.